18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
AgeNot listed
SponsorAssiut University
About this trial
To compare the diagnostic performance of 18-F PSMA PET/CT and CT alone in initial staging, assessment of therapy response, as well as evaluation of biochemical recurrence of prostatic cancer patients
The main question it aims to answer is:
Does 18-F PSMA PET/CT have a superior role over CT in evaluation of prostatic cancer patients?
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Patients with claustrophobia
Patients refuse to do the scan
Trial population
Patients with known prostate cancer referred for doing 18F-PSMA PET/CT as a part of their initial evaluation, assessing of therapy response, or detection of suspected biochemical recurrence
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Comparing 18-F PSMA PET/CT and CT in evaluation of prostatic cancer patients
Comparison of diagnostic performance of 18-F PSMA PET/CT and CT in staging, assessment of therapy response and evaluation of biochemical recurrence
Time frame
2 yearsSecondary outcomes
1
Correlation between quantitative measures and other clinical, pathological and laboratory measures
Correlation between quantitative measures and tumor burden of 18-F PSMA PET/CT with clinical, pathological and laboratory data including serum PSA, and Gleason Score
Time frame
2 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: